InsidersTradesSigma
Total declarations
Companies
▲ Purchases (15 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
15
Disclosed sells
0
T+90 hit rate
64%
T+90 mean return
+1.0%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by FOEHR MATTHEW W, Président. Officer active across 5 companies, notably Ligand Pharmaceuticals INC. Aggregated, 48 filings have been published. Breakdown: 15 buys · 0 sell. Total volume traded: €7.7m. Activity tracked since 28 May 2021. The latest transaction was disclosed on 11 April 2025 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations48 total
20,786 shares@ US$8.0033.5% of flowCommon Stock, par value $0.00001 per shareSEC:0000950170-25-053867:0
36,458 shares0Common StockSEC:0001628280-25-016993:0
26,549 sharesCommon StockSEC:0001846253-25-000013:0
77,003 shares0Common StockSEC:0001846253-25-000004:0
26,555 sharesCommon StockSEC:0001846253-24-000097:0
31,074 shares@ US$3.681.4% of flowCommon StockSEC:0001846253-24-000090:0
18,644 shares@ US$3.680.8% of flowCommon StockSEC:0001846253-24-000058:0
240,000 shares@ US$4.41612.5% of flowCommon StockSEC:0001846253-24-000036:0
Ideal exit: 18 Feb 2025 (T+270)
1,431,618 sharesCommon StockSEC:0001846253-24-000014:0
36,458 sharesCommon StockSEC:0002001011-24-000045:0
93,222 shares@ US$3.684.0% of flowCommon StockSEC:0002001011-24-000037:0
225,000 shares@ US$5.1913.7% of flowCommon StockSEC:0002001011-24-000033:0
Ideal exit: 17 Dec 2024 (T+270)
10,770 sharesCommon StockSEC:0002001011-24-000021:0
33,173 sharesCommon StockSEC:0002001011-24-000005:0
200,000 shares@ US$5.0511.9% of flowCommon StockSEC:0002001011-23-000015:0
Ideal exit: 7 Sept 2024 (T+270)
26,556 sharesCommon StockSEC:0002001011-23-000009:0
95,000 shares@ US$4.26864.8% of flowCommon StockSEC:0000950170-23-062463:0
Ideal exit: 6 Aug 2024 (T+270)
45,000 shares@ US$5.482.9% of flowCommon StockSEC:0001846253-23-000099:0
Ideal exit: 10 May 2024 (T+270)
115,000 shares@ US$4.526.1% of flowCommon StockSEC:0001846253-23-000079:0
Ideal exit: 5 Mar 2024 (T+270)
440,000 shares@ US$3.4017.4% of flowCommon StockSEC:0001846253-23-000072:0
Ideal exit: 6 Feb 2024 (T+270)
109,375 shares0Common StockSEC:0001846253-23-000042:0
9,184 shares@ US$3.800.4% of flowCommon StockSEC:0001846253-23-000013:0
79,665 shares0Common StockSEC:0000899243-23-001017:0
11,624 shares@ US$3.660.5% of flowCommon StockSEC:0000899243-22-039581:0
150,000 shares@ US$3.76516.8% of flowCommon StockSEC:0000899243-22-038479:0
Ideal exit: 8 Sept 2023 (T+270)
25 of 48 declarations
About FOEHR MATTHEW W
FOEHR MATTHEW W serves as President and COO at Ligand Pharmaceuticals Inc and Viking Therapeutics, Inc. In this role, he is responsible for the strategic direction of the companies and managing operations. His leadership is essential in ensuring the growth and sustainability of the companies.
